Health and Zimmer Biomet Holdings, a global medical technology leader, has announced a multi-year co-marketing agreement to commercialise GenAI-powered engagement solutions that advance value-based orthopaedic care and health equity. During the multi-year agreement, Zimmer Biomet will commercialise RevelAi Health’s patient care-management platform, care team dashboard for providers and any future products or services.
“Leveraging generative AI to streamline clinical care workflows while addressing socio-demographic disparities is a unique opportunity to drive equitable value-based outcomes,” said Christian Péan MD, MS, CEO of RevelAi Health and an orthopedic trauma surgeon at Duke University School of Medicine. “Our AI-enabled asynchronous care model delivers personalised, timely, and effective patient care while reducing clinician burnout. Our collaboration with Zimmer Biomet is a significant step towards ensuring that every patient receives the care they deserve.”
RevelAi health is a software as a service (SAAS) health technology company that specialises in cutting-edge GenAI population health solutions. RevelAi Health’s clinician-validated large language model helps healthcare providers transition seamlessly to value-based care, meeting essential CMS (Centers for Medicare and Medicaid Services) requirements, including Patient Reported Outcome measures and Social Drivers of Health (SDOH) Screening.
